Introduction

Healthy joints rely on cartilage to move smoothly, and when it wears, pain and stiffness can follow. Two options people frequently ask about are ChondroFiller and stem cell therapy. Before comparing them, it helps to understand that these are not simply two competing injections: one pathway is non-surgical, one involves keyhole surgery, and mesenchymal stem cells (MSCs) can play a role in the surgical route. This article sets out the distinctions clearly, with realistic expectations throughout.

ChondroFiller: The Collagen Scaffold and Its Two Delivery Pathways

ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured as an acellular (cell-free) material. In appropriate conditions it self-gels in around three to five minutes, forming a porous three-dimensional matrix that provides physical support within a chondral defect and recruits the patient's own progenitor cells to remodel the scaffold towards cartilage over time.

It is important to understand that ChondroFiller can reach the joint by two quite different routes, each suited to different clinical circumstances.

The ChondroFiller Injection (Non-Surgical)

For accessible lesions, smaller joints, or patients who cannot or do not wish to undergo surgery, ChondroFiller can be placed via an ultrasound-guided outpatient injection. There is no theatre, no incision, and no general anaesthetic. The collagen gel is guided into the affected area, where it may settle over worn surfaces to add a protective, regenerative layer. A 2023 study of an acellular collagen matrix injection for thumb-base osteoarthritis reported improvements in pain and grip strength (Corain et al., 2023), though individual responses vary. ChondroFiller is not a cure for arthritis, and benefits cannot be guaranteed.

The Liquid Cartilage Surgical Procedure

For larger or load-bearing defects — commonly in the knee, hip, shoulder, or ankle — the appropriate delivery pathway is keyhole surgery, not an injection. Professor Paul Y. F. Lee's Lee Liquid Cartilage Protocol (the LLC Protocol) is a minimally invasive arthroscopic surgical technique that places the ChondroFiller scaffold under controlled conditions alongside biological adjuncts: platelet-rich fibrin, platelet-rich plasma, and tranexamic acid. The procedure takes place in theatre under anaesthetic and is followed by a structured rehabilitation programme. The ChondroFiller device's published CE-mark evidence belongs to the material itself; the Liquid Cartilage name refers to Professor Lee's surgical protocol, not to ChondroFiller alone.

Where Stem Cells Fit In

Mesenchymal stem cells (MSCs) — typically derived from bone marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue (mFAT) — can be incorporated into the Liquid Cartilage surgical protocol as an optional adjunct, where clinical assessment indicates they may add benefit. MSCs release trophic and immunomodulatory factors that may support chondrogenesis and temper post-operative inflammation; they act synergistically with the fibrin and collagen scaffold in the surgical setting.

MSCs in this context are not a standalone treatment — they form part of a single-stage procedure performed at the same time as the scaffold placement, within the Liquid Cartilage surgical protocol. This is distinct from standalone stem cell therapy, which involves harvesting cells (usually from bone marrow or adipose tissue), processing them separately, and reintroducing them into the joint in a multi-step process that does not use the ChondroFiller scaffold.

Standalone Stem Cell Therapy: A Separate Track

Standalone stem cell therapy for joint conditions involves several procedural steps: harvesting cells from bone marrow or fat, processing or concentrating them, and then delivering them intra-articularly. Because it involves a laboratory or centrifugation phase, it is procedurally more involved than a single injection and carries its own evidence base. Clinical experience in the orthobiologics literature suggests that bone marrow aspirate concentrate can produce meaningful symptom improvement in knee osteoarthritis, though results vary with disease severity and technique. Standalone stem cell therapy is a different clinical pathway from the Liquid Cartilage surgical protocol, even though both may involve bone marrow or adipose-derived cells at some stage.

Who Each Approach May Suit

Suitability is individual and requires specialist assessment. As a general guide:

• The ChondroFiller injection may suit patients with osteoarthritis or focal joint wear who prefer a non-surgical, single-stage outpatient option — often where the defect is accessible and the joint is not severely affected.
• The Liquid Cartilage surgical procedure may suit patients with larger or load-bearing chondral defects in major joints, where controlled arthroscopic delivery of the scaffold, combined with biological adjuncts, is more appropriate than an injection alone. MSCs may be incorporated at the surgeon's discretion.
• Standalone stem cell therapy occupies a different space and may be considered where the clinical picture does not align with the scaffold-based approaches described above.
• In all cases, joint stability, alignment, defect size and location, and overall health are relevant factors. Advanced arthritis is generally not an indication for cartilage regeneration procedures.

Conclusion

ChondroFiller is a single collagen scaffold material that can be delivered either as a non-surgical outpatient injection or, where surgery is appropriate, as the core of Professor Lee's Liquid Cartilage keyhole surgical protocol — the latter optionally incorporating the patient's own mesenchymal stem cells as an adjunct. Standalone stem cell therapy is a distinct multi-step pathway. The right choice depends on the joint, the defect, and individual clinical circumstances. Consultation with a specialist experienced in cartilage regeneration is the appropriate first step. At the London Cartilage Clinic, assessment covers all relevant options and sets realistic expectations.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.